ASNS Synthetic Lethal Targeting for Durable Cancer Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells endure nutrient-restricted environments by rewiring metabolic pathways, making it challenging to develop durable therapeutic responses, particularly in rapidly proliferating tumors.
Innovation Solution
Targeting synthetic lethal partners of asparagine synthetase (ASNS) using a combination of asparagine restriction agents and inhibitory agents, such as small molecules, siRNA, CRISPR-Cas9 complexes, or TALENs, to disrupt pathways like AAR, MAPK, and RTK, thereby suppressing tumor proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If asparagine restriction agents are used alone, then tumor cell growth is initially suppressed, but cancer cells compensate by upregulating ASNS expression and rewiring metabolic pathways, leading to therapeutic resistance
Solution Approach 1:
The patent divides the therapeutic approach into multiple targeted components: asparagine restriction agents (to deplete asparagine) combined with inhibitors of specific synthetic lethal partners (ASNS SL partners) such as ATF4, GCN2, eIF2α, BRAF, MEK1, and MNK1. This segmentation prevents cancer cells from compensating through single-pathway adaptation, as multiple interconnected pathways are simultaneously blocked.
Solution Approach 2:
The patent combines asparagine restriction therapy with inhibition of ASNS synthetic lethal partners in a combinatorial approach. This merging of therapeutic modalities creates synergistic effects that overcome metabolic rewiring by blocking both asparagine depletion and the compensatory stress response pathways that cancer cells activate to survive nutrient restriction.
2Reliability
If combinatorial therapeutic approaches targeting multiple pathways are used, then therapeutic efficacy is improved, but treatment complexity and potential off-target effects increase
Solution Approach 1:
The patent applies local quality by selectively targeting specific ASNS synthetic lethal partners that are dysregulated in particular cancer types. For example, BRAF and MEK1 inhibitors are specifically applied to melanoma with BRAF mutations, while ATF4 and GCN2 inhibition is targeted to cancers with high ASNS expression. This precision reduces unnecessary treatment complexity while maintaining high efficacy.
Solution Approach 2:
The patent incorporates feedback mechanisms through biomarker monitoring to guide combinatorial therapy selection. ASNS expression levels, phosphorylation status of stress response proteins (p-eIF2α, p-GCN2), and pathway activation markers are monitored to determine which combination of asparagine restriction agents and SL partner inhibitors should be administered, thereby optimizing treatment while minimizing unnecessary complexity.
3Productivity
If asparagine restriction is applied to rapidly proliferating tumors, then initial growth suppression is achieved, but tumors develop adaptive responses through metabolic rewiring that reduce therapeutic durability
Solution Approach 1:
The patent employs preliminary action by pre-emptively blocking compensatory pathways before cancer cells can adapt to asparagine restriction. By simultaneously administering asparagine restriction agents with inhibitors of ASNS SL partners (such as ATF4, GCN2, and eIF2α inhibitors), the therapy prevents the metabolic rewiring that would otherwise allow tumors to recover and continue proliferating.
Data Source
AI summary
Described herein are methods and compositions for diagnosing, treating, or ameliorating symptoms of cancer, including pancreatic cancer and melanoma, with Asparagine Synthetase (ASNS) synthetic lethal partners.